AtheroGenics AGI-1067 Pivotal Data Expected In Late Q1
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
AtheroGenics’ atherosclerosis drug candidate AGI-1067 may qualify for multiple labeling claims in patient subpopulations including elderly patients, diabetics and women, CEO Russell Medford stated during the JP Morgan Healthcare Conference in San Francisco Jan. 10.